Table 3.
Baseline characteristics of study patients and delivered CRRT.
| Group 1 | Group 2 | Group 3 | |
|---|---|---|---|
| Demographics* | |||
| Age (years) | 63 (43–86) | 68 (37–88) | 67 (53–83) |
| Weight (kg) | 80 (53–116) | 86 (56–124) | 79 (41–130) |
| Male sex, n (%) | 7 (50) | 7 (50) | 5 (36) |
| APACHE II* | 28.1 (19–44) | 26 (13–36) | 23.2 (15–29) |
| RIFLE score, points*,† | 37 | 39 | 39 |
| Delivered CRRT* | |||
| CRRT treatment duration (h) | 82 (17–278) | 115 (37–207) | 96 (29–210) |
| CRRT treatment mode | CVVHDF | CVVHDF | CVVHDF |
| Effluent flow (ml/kg/h) calculated on active treatment time*,‡ | 23.7 (13–45) | 21.9 (15–30) | 18 (10–20) |
| Proportion of ordered dose delivered* | 85.3% | 87.5% | 91.8% |
| Anticoagulation* | None 3 | None 2 | None 2 |
| Heparine 9 | Heparine 11 | Heparine 10 | |
| Prostacycline 1 | Prostacycline 1 | Prostacycline 2 | |
| Phosphate supplementation§ (mmol/CRRT treatment day) | 11 (0–35) | 3 (0–13) | 0 (0) |
*
Differences between groups were not statistically significant. Numbers in parentheses are range, unless stated otherwise.
†
We scored RIFLE-risk (R, risk; I, injury; F, failure; L, loss of kidney function; E, end-stage kidney disease) as 1, injury as 2, and failure as 3.
‡
The dialysis dose in CRRT is expressed in terms of ml of effluent (dialysate+ultrafiltrate) per kg of body weight (BW) per hour (ml/kg/h).23
§
Statistical differences were as follows: between groups 1 and 2 (P=0.046), between groups 1 and 3 (P≤0.001), and between groups 2 and 3 (P=0.003).